Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma

The treatment landscape of metastatic urothelial cancer (mUC) remained unchanged for over 30 years until the approval of immune checkpoint inhibitors (ICIs) in 2016. Since then, several ICIs have been approved for the treatment of mUC. In addition, recent molecular characterization of bladder cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Benjamin, David J, Mar, Nataliya, Rezazadeh Kalebasty, Arash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520173/
https://www.ncbi.nlm.nih.gov/pubmed/36186672
http://dx.doi.org/10.1177/11795549221126252
_version_ 1784799566086799360
author Benjamin, David J
Mar, Nataliya
Rezazadeh Kalebasty, Arash
author_facet Benjamin, David J
Mar, Nataliya
Rezazadeh Kalebasty, Arash
author_sort Benjamin, David J
collection PubMed
description The treatment landscape of metastatic urothelial cancer (mUC) remained unchanged for over 30 years until the approval of immune checkpoint inhibitors (ICIs) in 2016. Since then, several ICIs have been approved for the treatment of mUC. In addition, recent molecular characterization of bladder cancer has revealed several subtypes, including those harboring fibroblast growth factor receptor (FGFR) mutations and fusion proteins. Erdafitinib, a pan-FGFR inhibitor, was approved for the treatment of metastatic/advanced UC in 2019. Some available evidence suggests ICI may have inferior response in advanced FGFR+ UC for unclear reasons, but may possibly be related to the tumor microenvironment. Several ongoing trials are evaluating erdafitinib in metastatic/advanced UC including the ongoing phase IB/II NORSE trial combining erdafitinib plus ICI, which may prove to offer a more robust and durable response in patients with FGFR+ metastatic/advanced UC.
format Online
Article
Text
id pubmed-9520173
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-95201732022-09-30 Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma Benjamin, David J Mar, Nataliya Rezazadeh Kalebasty, Arash Clin Med Insights Oncol Review The treatment landscape of metastatic urothelial cancer (mUC) remained unchanged for over 30 years until the approval of immune checkpoint inhibitors (ICIs) in 2016. Since then, several ICIs have been approved for the treatment of mUC. In addition, recent molecular characterization of bladder cancer has revealed several subtypes, including those harboring fibroblast growth factor receptor (FGFR) mutations and fusion proteins. Erdafitinib, a pan-FGFR inhibitor, was approved for the treatment of metastatic/advanced UC in 2019. Some available evidence suggests ICI may have inferior response in advanced FGFR+ UC for unclear reasons, but may possibly be related to the tumor microenvironment. Several ongoing trials are evaluating erdafitinib in metastatic/advanced UC including the ongoing phase IB/II NORSE trial combining erdafitinib plus ICI, which may prove to offer a more robust and durable response in patients with FGFR+ metastatic/advanced UC. SAGE Publications 2022-09-27 /pmc/articles/PMC9520173/ /pubmed/36186672 http://dx.doi.org/10.1177/11795549221126252 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Benjamin, David J
Mar, Nataliya
Rezazadeh Kalebasty, Arash
Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
title Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
title_full Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
title_fullStr Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
title_full_unstemmed Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
title_short Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
title_sort immunotherapy with checkpoint inhibitors in fgfr-altered urothelial carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520173/
https://www.ncbi.nlm.nih.gov/pubmed/36186672
http://dx.doi.org/10.1177/11795549221126252
work_keys_str_mv AT benjamindavidj immunotherapywithcheckpointinhibitorsinfgfralteredurothelialcarcinoma
AT marnataliya immunotherapywithcheckpointinhibitorsinfgfralteredurothelialcarcinoma
AT rezazadehkalebastyarash immunotherapywithcheckpointinhibitorsinfgfralteredurothelialcarcinoma

Ejemplares similares